For further information about ICON, visit: www.iconplc.com, This press release contains forward-looking statements, including statements regarding our financial guidance. These statements are ...

ICON Public Limited Company faces a dynamic and challenging market environment in 2025, marked by elevated cancellations and delays in trial starts. The company has adjusted its guidance to ...

The most recent guidance for Icon (ICLR) was reported on April 30, 2025 for the full year 2025. The company provided earnings per share guidance in the range of $12.75 to $14.25, compared to the ...

ICON also lowered its full-year 2024 guidance, now expecting revenue between $8.26-$8.3 billion, down from its previous forecast and below the $8.51 billion consensus. The company cut its adjusted ...

Full year 2025 financial guidance excludes any potential share repurchase or additional M&A activity. CEO Dr. Steve Cutler commented, “ICON continues ... decisions. The word "expected" and ...

Full year 2025 revenue guidance in the range of $8,050 - $8,650 million; midpoint of $8,350 million representing growth of approximately 1% over full year 2024 revenue guidance midpoint.

ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025.